<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990037</url>
  </required_header>
  <id_info>
    <org_study_id>CAN04CLIN003</org_study_id>
    <nct_id>NCT04990037</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma</brief_title>
  <acronym>CAPAFOUR</acronym>
  <official_title>A Phase 1b Dose Escalation and Expansion Study of CAN04, a Monoclonal Antibody Targeting IL1RAP, in Combination With Modified FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantargia AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantargia AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will consider the safety and effectiveness of a study drug, CAN04, in combination&#xD;
      with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2021</start_date>
  <completion_date type="Anticipated">August 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of TEAEs (Treatment-emergent adverse events)</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with DTLs (dose-limiting toxicities)</measure>
    <time_frame>Up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with 1 or more TEAEs leading to dose modifications</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with grade ≥ 3 TEAEs</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with grade ≥ 3 TEAEs</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with 1 or more TEAEs leading to treatment discontinuation</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with 1 or more TEAEs leading to dose modification</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with 1 or more TEAEs leading to treatment discontinuation</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with 1 or more SAEs (serious adverse events)</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with 1 or more SAEs</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of CAN04 and Folfirnox</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADAs) against CAN04</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum IL-6 (Interleukin-6) concentration</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum CRP (C-reactive protein) concentration</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
    <description>Proportion of subjects with partial response (PR) or complete response (CR) to study treatment as defined by iRECIST (immune-related response evaluation criteria in solid tumors) and measured by radiological assessment (CT/MRI Scan)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 36 months after 1st dose of last subject (or death)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>CAN04 and FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive bi-weekly doses of CAN04 in combination with FOLFIRINOX given as standard regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAN04</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>CAN04 and FOLFIRINOX</arm_group_label>
    <other_name>Nadunolimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>CAN04 and FOLFIRINOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is capable to understand and willing to provide written informed consent&#xD;
             before any study-related activities (study-related activities are any procedures that&#xD;
             would not have been performed during normal management of the subject's disease).&#xD;
&#xD;
          -  The subject is at least 18 years of age.&#xD;
&#xD;
          -  The subject has been diagnosed with stage IV PDAC (Pancreatic Ductal Adenocarcinoma)&#xD;
             and is amenable to first-line systemic therapy. The subject must have measurable&#xD;
             disease that is histologically or cytologically confirmed.&#xD;
&#xD;
          -  The subject has an ECOG (Eastern Cooperative Oncology Group) performance status of 0&#xD;
             or 1.&#xD;
&#xD;
          -  The subject has a primary or metastatic lesion amenable to biopsy and is willing to&#xD;
             undergo repeat biopsies, unless a biopsy would not be safe in the opinion of the&#xD;
             investigator and in agreement by the sponsor and medical monitor (or designee).&#xD;
&#xD;
          -  The subject has clinically adequate bone marrow, hepatic, and renal function based on&#xD;
             clinical laboratory test values at screening within the following ranges:&#xD;
&#xD;
               -  Creatinine clearance &gt;30 mL/min calculated by Cockcroft-Gault formula&#xD;
&#xD;
               -  Haemoglobin &gt;90 g/L (blood transfusions during the screening period are not&#xD;
                  allowed)&#xD;
&#xD;
               -  Absolute neutrophil count &gt;1.5 × 109/L (usage of growth factors, such as G-CSF&#xD;
                  (Granulocyte Colony-Stimulating Factor), during the screening period is not&#xD;
                  allowed)&#xD;
&#xD;
               -  Platelets &gt;100 × 109/L&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 × ULN unless due to Gilbert's syndrome&#xD;
&#xD;
               -  AST and ALT ≤3 × ULN (or &lt;5 × ULN for subjects with hepatic metastases)&#xD;
&#xD;
          -  The subject has a QT interval corrected using Fridericia's formula (QTcF) of ≤ 480&#xD;
             milliseconds at screening.&#xD;
&#xD;
          -  Female subjects of childbearing potential (more info can be found in the protocol) and&#xD;
             male subjects with female partners of childbearing potential must be willing to adhere&#xD;
             to contraceptive requirements as detailed in the protocol, from at least 1 month prior&#xD;
             to study entry to at least 4 months after the last dose of study treatment.&#xD;
&#xD;
          -  The subject has suitable venous access for safe drug administration and the study-&#xD;
             required drug concentration and pharmacodynamic sampling.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received previous radical radiotherapy, chemotherapy, or&#xD;
             investigational therapy for the treatment of metastatic disease.&#xD;
&#xD;
               -  Prior treatment with 5-FU or gemcitabine administered as a radiation sensitiser&#xD;
                  during and up to 4 weeks after radiation therapy, is allowed; however, if there&#xD;
                  is lingering toxicity (Grade &gt;1), then the sponsor should be consulted.&#xD;
&#xD;
               -  If a subject received adjuvant or neoadjuvant chemotherapy, tumour recurrence or&#xD;
                  disease progression must have occurred no sooner than 6 months after completing&#xD;
                  the last dose.&#xD;
&#xD;
          -  Subjects with uncontrolled brain metastases; however, subjects are allowed if they&#xD;
             have been previously treated with surgery, whole-brain radiation, and/or stereotactic&#xD;
             radiosurgery and are considered controlled (with ≤10 mg/day of prednisone or&#xD;
             equivalent) at the time of receiving the first dose of CAN04. For asymptomatic&#xD;
             subjects, screening brain imaging is not required.&#xD;
&#xD;
          -  Subjects with endocrine or acinar pancreatic carcinoma.&#xD;
&#xD;
          -  Subjects with an active severe infection requiring parenteral antibiotics at the time&#xD;
             of enrolment or subjects currently receiving oral antibiotics as a continuation of a&#xD;
             previous course of parenteral antibiotics.&#xD;
&#xD;
          -  Subjects with peripheral sensory neuropathy Grade ≥2.&#xD;
&#xD;
          -  Subjects with a serious uncontrolled medical disorder that, in the opinion of the&#xD;
             investigator or medical monitor, makes it unwise for the subject to participate in the&#xD;
             study or that might jeopardise compliance with the protocol.&#xD;
&#xD;
          -  Subjects with psychiatric illness/social circumstances that would limit compliance&#xD;
             with study requirements and substantially increase the risk of AEs (Adverse Events) or&#xD;
             has compromised ability to provide written informed consent.&#xD;
&#xD;
          -  Subjects with an active second invasive malignancy with the exception of stable&#xD;
             prostate cancer on watchful waiting.&#xD;
&#xD;
          -  Subjects with uncontrolled or significant cardiovascular disease defined as NYHA (New&#xD;
             York Heart Association) classification III or IV.&#xD;
&#xD;
          -  Subjects with congenital long QT syndrome.&#xD;
&#xD;
          -  Subjects with a history of autoimmune disease requiring systemic immunosuppressive&#xD;
             therapy (daily prednisone equivalent doses &gt;10 mg/day).&#xD;
&#xD;
          -  Subjects with known hepatitis B virus surface antigen seropositive or detectable&#xD;
             hepatitis C infection viral load. NOTE: Subjects who have positive hepatitis B core&#xD;
             antibody or hepatitis B surface antigen antibody can be included but must have an&#xD;
             undetectable hepatitis B viral load.&#xD;
&#xD;
          -  Subjects with a known history of any other relevant congenital or acquired&#xD;
             immunodeficiency other than HIV infection. NOTE: Subjects testing positive for HIV are&#xD;
             NOT excluded from this study, but HIV- positive subjects must meet the following&#xD;
             criteria:&#xD;
&#xD;
               -  Have CD4+ T-cell (CD4+) counts ≥350 cells/µL.&#xD;
&#xD;
               -  Have not had an opportunistic infection within the past 12 months. Subjects on&#xD;
                  prophylactic antimicrobials can be included in the study.&#xD;
&#xD;
               -  Should be on established antiretroviral therapy for at least 4 weeks.&#xD;
&#xD;
               -  Have an HIV viral load less than 400 copies/mL prior to enrolment.&#xD;
&#xD;
          -  Subjects who receive a live vaccination, etanercept, or other TNF-α (Tumor Necrosis&#xD;
             Factor-alpha) inhibitors during or just prior to (within 28 days of first dose of&#xD;
             study treatment) participation in this study.&#xD;
&#xD;
          -  Subjects who have had a hospitalization for bowel obstruction within 12 weeks prior to&#xD;
             enrolment.&#xD;
&#xD;
          -  Subjects with a known bleeding disorder or coagulopathy. NOTE: Subjects on stable&#xD;
             anticoagulant therapy are allowed at the discretion of the investigator; however,&#xD;
             these subjects should be monitored more frequently.&#xD;
&#xD;
          -  Subjects with a known or suspected allergy to any study treatment or related products,&#xD;
             including platinum-based chemotherapeutic agents.&#xD;
&#xD;
          -  Female subjects who are pregnant or breastfeeding or trying to become pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio Garcia-Ribas, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cantargia AB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignacio Garcia-Ribas, MD, PhD</last_name>
    <phone>+46 46 2756260</phone>
    <email>Clinicaltrials@cantargia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dorthe da Graça Thrige, PhD</last_name>
    <email>Clinicaltrials@cantargia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>EDOG - Institut Bergonie - PPDS</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Italiano</last_name>
      <phone>+33556333244</phone>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>EDOG Institut de Cancerologie de l'Ouest - PPDS</name>
      <address>
        <city>Nantes</city>
        <zip>44100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Hiret, MD</last_name>
      <phone>+33240679978</phone>
      <email>sandrine.hiret@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Le Sourd, MD</last_name>
      <phone>+33299253089</phone>
      <email>s.lesourd@rennes.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Macarulla Mercade, MD</last_name>
      <phone>+34932746000</phone>
      <phone_ext>2658</phone_ext>
      <email>tmacarulla@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO l'Hospitalet - Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariona Calvo Campos, MD</last_name>
      <phone>+34932607744</phone>
      <email>mcalvo@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Muñoz Martin, MD</last_name>
      <phone>+34914269394</phone>
      <email>andresmunmar@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>START MADRID_Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Hernandez Guerrero, MD</last_name>
      <phone>+3491554800</phone>
      <phone_ext>2708</phone_ext>
      <email>tatiana.hernandez@startmadrid.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Garcia Carbonero, MD</last_name>
      <phone>+34913908923</phone>
      <email>rgcarbonero@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

